The largest database of trusted experimental protocols

EGFR 29 Mutations Detection Kit

Manufactured by Amoy Diagnostics
Sourced in United States, China

The EGFR 29 Mutations Detection Kit is a laboratory diagnostic tool designed to detect the presence of specific genetic mutations in the epidermal growth factor receptor (EGFR) gene. The kit utilizes advanced molecular techniques to identify 29 known EGFR mutations, providing healthcare professionals with valuable information for clinical decision-making.

Automatically generated - may contain errors

12 protocols using EGFR 29 Mutations Detection Kit

EGFR mutations were analysed with the amplification-refractory mutation system (ARMS). Primary tumours, lymph nodes, distant metastases, and pleural effusion specimens were excised, aspirated, or biopsied; fixed in 10% neutral buffered formalin; and then embedded in paraffin. DNA was extracted from the formalin-fixed, paraffin-embedded tissue sections, and a Qiagen FFPE Tissue Kit (Netherlands Roots NV) was used according to the manufacturer’s instructions. PCR was carried out with the Mx3000PtM system (Stratagene, La Jolla, USA) using an EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, People’s Republic of China), and the results were interpreted according to the manufacturer’s instructions. Molecular analysis of EGFR mutations was defined as the mutation status of EGFR exons 18, 19,21, 20. Otherwise, other types of EGFR mutations were defined as wild-type EGFR [4 (link), 17 (link)].
+ Open protocol
+ Expand
The overall distribution of EGFR mutations is presented in Figure 1B. EGFR mutations were analyzed according to the principle of the amplified drug resistance mutation system (ARMS). Primary tumors, lymph nodes, distant metastases or pleural effusion specimens were excised, aspirated or biopsied followed by 10% neutral buffered formalin fixation and paraffin embedding. DNA was extracted from formalin-fixed paraffin-embedded tissue sections and analyzed using the Qiagen FFPE Tissue Kit (Netherlands, Roots, NV) according to the manufacturer’s instructions. PCR was performed using the Mx3000PtM System (Stratagene, La Jolla, CA, USA) and the EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, People’s Republic of China), and the results were interpreted according to the manufacturer’s instructions.
+ Open protocol
+ Expand
EGFR mutations were analyzed based on the principle of the amplification refractory mutation system (ARMS). Briefly, resected tumor samples were fixed in 10% neutral buffered formalin and embedded in paraffin wax. Extracted DNA was used for PCR with the Mx3000PtM (Stratagene, La Jolla, USA) using the EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, China).
+ Open protocol
+ Expand
DNA was extracted from the FFPE tumor tissues using Amoydx FPE DNA Kit (Amoy Diagnostics, Xiamen, China) according to protocols. Polymerase chain reaction (PCR) was performed at the Mx3000PTM real-time PCR system (Strata gene, La Jolla, USA). EGFR mutations were detected by EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, China). We used ΔCt method to quantify the amplification. If ΔCt values were higher than 2.0, the patient was identified as “EGFR mutant”; otherwise, the patient was identified as “EGFR wild-type”.
+ Open protocol
+ Expand

EGFR mutation detection was conducted using the Amplification‐Refractory Mutation System. FFPE DNA extraction kit (Amoy Diagnostics, Xiamen, China) was used to extract tumor DNA. EGFR mutation was detected by EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, China) using 80 ng DNA. The procedures were followed‐up as described in the protocol. PCR was performed on a Stratagene Mx3000P cycler (Agilent, Santa Clara, CA, USA) using the following program: Five minutes at 95°C (one cycle); 25 seconds at 95°C, 20 seconds at 64°C, and 20 seconds at 72°C (15 cycles); 25 seconds at 93°C, 35 seconds at 60°C, and 20 seconds at 72°C (31 cycles). The results were determined as described in the protocol.
+ Open protocol
+ Expand
The status of EGFR mutations was detected by histological examination of primary tumors, metastatic lymph nodes or organs that were obtained by surgical resection, fiberoptic bronchoscopy biopsy, or fine-needle puncture. In all cases, the samples were fixed in 10% buffered neutral formalin and embedded in paraffin wax. According to instructions provided by the manufacturer, DNA was extracted from the formalin-fixed paraffin-embedded (FFPE) tissue sections using the QIAamp DNA FFPE Tissue Kit (Qiagen NV, Venlo, Netherlands). The polymerase chain reaction was conducted using a Mx3000PTM real-time PCR system (Stratagene, La Jolla, USA). Amplification-refractory mutation system along with an EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen) was used to detect the status of EGFR mutations. EGFR mutant tumors were identified if exon mutations were detected; otherwise, wild-type tumors were determined.
+ Open protocol
+ Expand
Formalin-fixed paraffin-embedded (FFPE), fine/core needle aspiration, biopsy, or pleural effusion samples were used for the detection of alterations in the five genes. The detection using amplification-refractory mutation system (ARMS) was conducted as we had reported in previous studies (20 (link),21 (link)). EGFR mutation was detected by EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, China) as the protocol described, which covered 25 19del subtypes (Table S1). After patients were resistant to EGFR-TKIs, peripheral blood, fine/core needle aspiration, biopsy, or pleural effusion samples were used to detect EGFR T790M mutation using EGFR 29 Mutations Detection Kit.
+ Open protocol
+ Expand
EGFR mutations were analysed according to the principle of the amplified drug resistance mutation system (ARMS). Primary tumours or lymph nodes were simply excised, aspirated, or biopsied, followed by 10% neutral buffered formalin fixation and paraffin embedding. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue sections, and the Qiagen FFPE Tissue Kit (Netherlands Roots NV) was used according to the manufacturer's instructions. PCR was carried out using the Mx3000PTM system (Stratagene, La Jolla, USA) with an EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, People’s Republic of China), and the results were interpreted according to the manufacturer’s instructions. Molecular analysis of EGFR mutations was defined as mutations in EGFR exons 18, 19, 21, or 20; other types of EGFR mutations were defined as wild-type EGFR5 (link),37 (link).
+ Open protocol
+ Expand
EGFR mutations were analyzed based on the principle of the amplification refractory mutation system (ARMS). Briefly, resected, aspirated or biopsied primary tumor, lymph node, or distant metastasis samples or pleural effusion samples were fixed in 10% neutral buffered formalin and embedded in paraffin wax. The DNA was extracted from the formalin-fixed, paraffin-embedded tissue sections using the QIAamp DNA FFPE tissue kit (Qiagen NV, Venlo,Netherlands) according to the manufacturer’s instructions. Polymerase chain reaction was carried out with the Mx3000PtM (Stratagene, La Jolla, USA) using the EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, People’s Republic of China), and the result was interpreted according to the manufacturer’s instructions.
+ Open protocol
+ Expand
Bone biopsy was performed in each patient. The specimen was then handled with modified Ethylene Diamine Tetraacetic Acid (EDTA) decalcification (which is good at preserving antigenicity and DNA quality), instead of traditional acid decalcification. If bone metastasis form NSCLC was confirmed by the morphology and immunohistochemistry (IHC) results of specimen, EGFR mutations were analyzed under of the amplification refractory mutation system (ARMS) using the EGFR 29 Mutations Detection Kit (Amoy Diagnostics, Xiamen, PRC).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!